Asthenic Disorders in Elderly Patients With Arterial Hypertension: Management Potential of Meldonium

Стаценко, М. Е.; Недогода, С. В.; Туркина, С. В.; Tyshchenko, I. A.; Poletaeva, L. V.; Tsoma, V. V.; Ledyaeva, A. A.; Чумачок, Е В

doi:10.20996/1819-6446-2013-9-1-25-30

Cited by 8 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In diabetic rats treated with mildronate the triglyceride level was lower than in untreated rats from week 4 to week 6. In addi tion, in healthy mildronate treated rats the triglycer 4.76 ± 0.40* 6.10 ± 0.34* 8.44 ± 0.18* 9.66 ± 0.21* STZ + mildronate (group 8) 4.53 ± 0.14* 6.70 ± 0.27* 8.79 ± 0.29* 8.75 ± 0.33* , ** ide level was lower than in control group. Cholesterol was determined only in a pilot study; since mildronate did not influence cholesterol level this study was not continued (not shown).…”

Section: The Effect Of Mildronate On Lipid Metabolismmentioning

confidence: 85%

“…This pharmacological effect of mildr onate is achieved by inhibition of gamma butyrobe taine hydroxylase and decrease of fatty acid beta oxi dation [5]. In clinical practice mildronate was effective in the treatment of some complications of type 2 dia betes mellitus [6][7][8][9]. Experimental studies demon * To whom correspondence should be addressed.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in rats with the streptozotocin model of diabetes mellitus

Sokolovska

Rumaks

Karajeva

et al. 2012

Biochem. Moscow Suppl. Ser. B

View full text Add to dashboard Cite

Rats with the streptozotocin (STZ) model of diabetes mellitus were treated with mildronate (100 mg/kg daily, per os or intraperitoneally) for 6 weeks. Body weight, blood glucose, triglycerides, ketone body concentrations, percent of glycated hemoglobin (HbA1c%), glucose tolerance, and the development of neuropathic pain were monitored throughout the whole experiment. The mildronate treatment completely prevented the development of the diabetic neuropathy from the first week up to the end of experiment. In the group of diabetic animals treated with mildronate a significant decrease of blood glucose was observed on the fourth week of the treatment, the level of triglycerides decreased from the third to sixth weeks. Mildronate also decreased accumulation of glycated hemoglobin on the sixth week and improved glucose tolerance compared with untreated animals. The data obtained confirm applicability of mildronate for therapy of diabetes mellitus and its complications.

show abstract

Section: The Effect Of Mildronate On Lipid Metabolismmentioning

confidence: 85%

Section: Introductionmentioning

confidence: 99%

The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in rats with the streptozotocin model of diabetes mellitus

Sokolovska

Rumaks

Karajeva

et al. 2012

Biochem. Moscow Suppl. Ser. B

View full text Add to dashboard Cite

show abstract

“…Всем пациентам проведена модифицированная шкала оценки влияния утомленности (Modified Fatigue Impact Scale (MFIS-21)) [20]. В шкале выделены подшкалы, оценивающие влияние астении на физическую (вопросы 1-7, 9, 10) и умственную (8,(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) активность. На каждый вопрос возможны 5 вариантов ответа: «ни разу», «редко», «иногда», «часто», «почти всегда».…”

Section: цель исследованияunclassified

“…Клинические проявления астено-невротического синдрома наблюдаются уже на ранних стадиях артериальной гипертензии (АГ) [12]. При 1-й стадии АГ преобладают гиперстенические расстройства -раздражительность, беспокойство, тревога, суетливость, нарушение качества выполняемой работы.…”

unclassified

Asthenia – is a Visiting Card of Post-COVID, and its Treatment in Comorbid Patients

Авдей¹,

Кулеш²

2023

Рецепт

View full text Add to dashboard Cite

Представлено исследование эффективности и переносимости винпоцетина у пациентов с постковидным синдромом и артериальной гипертензией с начальными проявлениями недостаточности мозгового кровообращения. Показано снижение выраженности физической и психической астении у этих пациентов вне зависимости от пола, возраста, длительности постковидного синдрома и дозы препарата. A study of the efficacy and tolerability of vinpocetine in patients with post-covid syndrome and arterial hypertension with initial signs of cerebrovascular insufficiency is presented. A decrease in the severity of physical and mental asthenia in these patients was shown, regardless of gender, age, duration of the post-COVID syndrome and the dose of the drug.

show abstract

New opportunities in the treatment of asthenic symptoms after a new coronavirus infection

Shishkova¹,

Martynov

2022

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. Asthenia is an urgent problem during the pandemic of new coronavirus infection (COVID-19) because of its high frequency regardless of the severity of the disease.The purpose of this subanalysis of data from the multicenter controlled randomized clinical trial TONUS was to evaluate the efficacy and safety of meldonium therapy for аsthenia in COVID-19 survivors.Materials and methods. A total of 880 patients with asthenia who underwent COVID-19 within the last 6 months were included in the analysis. The efficacy of asthenia therapy was assessed by the MFI-20 scale, Schulte tables, and the General Clinical Impression (CGI) scale. All patients were previously randomized in two parallel branches of the TONUS study, including patients without concomitant disease in TONUS-1 (who received meldonium 500 mg/day for 14 days in the main group) and patients with cardiovascular or cerebrovascular disease in TONUS-2, who received meldonium at a dose of 1000 mg/day for 42 days in the main group. In both arms of the study, the drugs in the comparison groups were multivitamin complexes.Results. For the TONUS-1 groups.In the group of patients receiving meldonium compared with the control group (p < 0.001): total MFI-20 score decreased and was 31 (25; 40); MFI-20 –35 (–46; 23); performance value –5 (–11; –2) seconds; proportion of patients with significant improvement (by CGI-I) by the end of follow-up was 92.8%. For TONUS-2 groups.In the group of patients receiving meldonium compared with the control group (p < 0.001): total MFI-20 score decreased to 35 (27; 44); MFI-20 –34 (–46; –21), performance value –5 (–11; –2), proportion of patients with significant improvement (by CGI-I) by end of follow-up – 90.8%.Conclusion. Significant positive dynamics and regression of asthenia were noted in the groups of patients receiving meldonium in comparison with the control groups.

show abstract

Asthenic Disorders in Elderly Patients With Arterial Hypertension: Management Potential of Meldonium

Cited by 8 publications

References 3 publications

The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in rats with the streptozotocin model of diabetes mellitus

The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in rats with the streptozotocin model of diabetes mellitus

Asthenia – is a Visiting Card of Post-COVID, and its Treatment in Comorbid Patients

New opportunities in the treatment of asthenic symptoms after a new coronavirus infection

Contact Info

Product

Resources

About